satraplatin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastic agents, platinum derivatives 4703 129580-63-8

Description:

MoleculeDescription

Synonyms:

  • satraplatin
  • JM216
  • BMS 182751
  • BMY 45594
  • Molecular weight: 500.28
  • Formula: C10H22Cl2N2O4Pt
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XA04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Platinum compounds
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 cytostatic

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05807 KEGG_DRUG
C0216381 UMLSCUI
CHEBI:85609 CHEBI
CHEMBL3833367 ChEMBL_ID
91825658 PUBCHEM_CID
C081294 MESH_SUPPLEMENTAL_RECORD_UI
7780 INN_ID
DB04996 DRUGBANK_ID
8D7B37T28G UNII
1733681 RXNORM
428317007 SNOMEDCT_US

Pharmaceutical products:

None